{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:18:14Z","timestamp":1784161094130,"version":"3.55.0"},"reference-count":52,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T00:00:00Z","timestamp":1497484800000},"content-version":"vor","delay-in-days":45,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Hungarian National Research, Development and Innovation Office","award":["K109375"],"award-info":[{"award-number":["K109375"]}]},{"name":"Hungarian National Research, Development and Innovation Office","award":["K111938"],"award-info":[{"award-number":["K111938"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Over the past 5\u00a0years, a shift to the use of novel psychoactive substances (NPS) has been observed among opioid users. The aim of this study was to assess the potential reasons for NPS use among treatment\u2010seeking patients receiving opiate substitution therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A structured questionnaire was filled out by a sample of 198 opiate dependent patients of Hungary's National Institute of Psychiatry and Addiction. This questionnaire assessed demographics, treatment characteristics, lifetime substance use, potential reasons for NPS use, negative life events (Life Events Scale), and psychiatric symptoms (Brief Symptom Inventory).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The most frequent reasons for NPS use were curiosity, replacing other drugs, and easy availability. The majority of the respondents used synthetic cathinones and chose practical reasons, not psychopharmacological preferences. A series of binary logistic regressions indicated that lifetime amphetamine use (OR\u00a0=\u00a04.64, 95% CI [2.16, 9.96]) and more severe psychiatric symptoms (OR\u00a0=\u00a01.89, 95% CI [1.18, 3.04]) may predict NPS use. Time spent in treatment was a minor protective factor (OR\u00a0=\u00a00.92, 95% CI [0.86, 0.99]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Synthetic cathinones might still substitute amphetamine\u2010derivatives, although these NPS are no longer legal. There is a need for the regular screening of psychiatric symptoms and the use of family therapy among participants on opioid substitution programs.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2602","type":"journal-article","created":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T11:33:24Z","timestamp":1497526404000},"source":"Crossref","is-referenced-by-count":13,"title":["Novel psychoactive substance use among treatment\u2010seeking opiate users: The role of life events and psychiatric symptoms"],"prefix":"10.1002","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-8699","authenticated-orcid":false,"given":"M\u00e1t\u00e9","family":"Kapit\u00e1ny\u2010F\u00f6v\u00e9ny","sequence":"first","affiliation":[{"name":"Faculty of Health Sciences Semmelweis University  Budapest Hungary"},{"name":"Institute of Psychology E\u00f6tv\u00f6s Lor\u00e1nd University  Budapest Hungary"},{"name":"National Institute of Psychiatry and Addictions Ny\u00edr\u0151 Gyula Hospital  Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Farkas","sequence":"additional","affiliation":[{"name":"Institute of Psychology E\u00f6tv\u00f6s Lor\u00e1nd University  Budapest Hungary"},{"name":"National Institute of Psychiatry and Addictions Ny\u00edr\u0151 Gyula Hospital  Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia Andrea","family":"Pataki","sequence":"additional","affiliation":[{"name":"Institute of Psychology E\u00f6tv\u00f6s Lor\u00e1nd University  Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kiss","sequence":"additional","affiliation":[{"name":"National Institute of Psychiatry and Addictions Ny\u00edr\u0151 Gyula Hospital  Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janka","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Institute of Psychology E\u00f6tv\u00f6s Lor\u00e1nd University  Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3bert","family":"Urb\u00e1n","sequence":"additional","affiliation":[{"name":"Institute of Psychology E\u00f6tv\u00f6s Lor\u00e1nd University  Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Demetrovics","sequence":"additional","affiliation":[{"name":"Institute of Psychology E\u00f6tv\u00f6s Lor\u00e1nd University  Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/NBHIV.S12371"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2012.00519.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2013.05.009"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110378370"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.02.011"},{"key":"e_1_2_9_7_1","unstructured":"Center for Substance Abuse Treatment. (2004).Substance abuse treatment and family therapy. Treatment Improvement Protocol (TIP) Series No. 39. DHHS Publication No. (SMA) 05\u20104006. Rockville MD: Substance Abuse and Mental Health Services Administration"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2014.944291"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113199990622"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113480987"},{"key":"e_1_2_9_11_1","unstructured":"Derogatis L.R.(1975).Brief symptom inventory. Baltimore MD: Clinical Psychometric Research"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/34.3.162"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.1811"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2003.023200"},{"key":"e_1_2_9_15_1","unstructured":"EMCDDA. (2010).Drugnet Europe 70. EMCDDA: Lisbon."},{"key":"e_1_2_9_16_1","unstructured":"EMCDDA. (2011).Annual Report 2011: The state of the drugs problem in Europe. Publications Office of the European Union: Luxembourg."},{"key":"e_1_2_9_17_1","volume-title":"European drug report: Trends and developments","author":"EMCDDA","year":"2014"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000107564"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2011.00060"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jclp.1013"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkr018"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2013.846288"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2012.06.007"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-016-0105-2"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2512"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0031692"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2297"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2490"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.142.11.1259"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/10673229709030550"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/0097840X.1981.9936820"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-12-116"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2010.11.001"},{"issue":"5","key":"e_1_2_9_34_1","first-page":"134","article-title":"Head shop compound abuse amongst attendees of the Drug Treatment Centre Board","volume":"103","author":"McNamara S.","year":"2010","journal-title":"Irish Medical Journal"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2648.2001.01826.x"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e31828e1881"},{"issue":"2","key":"e_1_2_9_37_1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/FTD.0b013e318208b693","article-title":"Urine analysis of 3,4\u2010methylenedioxypyrovalerone in opioid\u2010dependent patients by gas chromatography\u2010mass spectrometry","volume":"33","author":"Ojanper\u00e4 I. A.","year":"2011","journal-title":"Therapeutic Drug Monitoring"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2016.75"},{"key":"e_1_2_9_39_1","volume-title":"Risk factors for youth suicide","author":"Paykel E. S.","year":"1991"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1625"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.796284"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/00981381003745103"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02145.x"},{"key":"e_1_2_9_44_1","unstructured":"SPSS Inc. (2008).SPSS statistics for Windows version 17.0. Chicago: SPSS Inc."},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2014.01.027"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1622"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2012.01.008"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.05.007"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.12.004"},{"key":"e_1_2_9_50_1","article-title":"The reinforcing and rewarding effects of methylone, a synthetic cathinone commonly found in \"bath salts\"","volume":"9","author":"Watterson L. R.","year":"2012","journal-title":"Journal of Addiction Research & Therapy, Suppl"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.12.011"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03502.x"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-10-3"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2602","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T05:08:27Z","timestamp":1696568907000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1002\/hup.2602"],"URL":"https:\/\/doi.org\/10.1002\/hup.2602","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"article-number":"e2602"}}